Article · 2 Sep 2026
Review articlePublished 30 May 2016
Extended-release intramuscular aripiprazole for maintenance pharmacotherapy in schizophrenia and related disorders
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aripiprazole is a third-generation antipsychotic. It is prepared in many different formulations including oral, intravenous and intramuscular. The intramuscular option is currently available in fast-acting form while the long-acting (extended-release, depot) formulation was just approved by the US FDA. The purpose of this article is to review the current literature regarding the long-acting formulation of aripiprazole. Medical literature published in English on ‘aripiprazole’ or ‘Abilify®’ (Otsuka America Pharmaceutical Inc., MD, USA) was found using Pubmed, Medline and EMBASE. Publications containing the words ‘depot’, ‘long-acting’ or ‘intramuscular’ in their title or abstract were utilized. In total, two publications were reviewed for the purposes of this article. There is a scarcity of publications on the effectiveness of long-acting aripiprazole in the treatment of schizophrenia and schizoaffective disorder. However, the available literature suggests that aripiprazole depot is a well tolerated, maintenance treatment option for schizophrenia.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Neuropsychiatry.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalNeuropsychiatry
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Leon Tourian”
- BylineArticles whose byline prints “Howard C Margolese”